MacroGenics Company Profile (NASDAQ:MGNX)

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MGNX
  • CUSIP: N/A
  • Web:
  • Market Cap: $638.97 million
  • Outstanding Shares: 35,012,000
Average Prices:
  • 50 Day Moving Avg: $19.76
  • 200 Day Moving Avg: $20.85
  • 52 Week Range: $16.75 - $33.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.95
  • P/E Growth: 0.02
Sales & Book Value:
  • Annual Revenue: $91.09 million
  • Price / Sales: 7.01
  • Book Value: $6.71 per share
  • Price / Book: 2.72
  • EBIDTA: ($59,800,000.00)
  • Net Margins: -55.01%
  • Return on Equity: -16.99%
  • Return on Assets: -14.99%
  • Current Ratio: 14.34%
  • Quick Ratio: 14.34%
  • Average Volume: 248,208 shs.
  • Beta: 2.8
  • Short Ratio: 12.56

Frequently Asked Questions for MacroGenics (NASDAQ:MGNX)

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by $0.09. The company earned $2.06 million during the quarter, compared to analysts' expectations of $5.88 million. MacroGenics had a negative return on equity of 16.99% and a negative net margin of 55.01%. View MacroGenics' Earnings History.

Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2017?

12 brokerages have issued 1 year price objectives for MacroGenics' shares. Their predictions range from $22.00 to $52.00. On average, they expect MacroGenics' share price to reach $33.89 in the next twelve months. View Analyst Ratings for MacroGenics.

What are analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:

  • 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (5/9/2017)
  • 2. BTIG Research analysts commented, "Based upon the 4Q16 earnings call hosted last week and our follow-up conversation with management, we present an outline of expected activities during 2017. The majority of the MGNX portfolio will be entering or expanding Phase 1 studies during 2017, which will weigh potential clinical catalysts towards 2H2017 and early 2018. The most significant identified clinical read-out during 2017 will likely be the futility analysis from the Margetuximab pivotal study. We reiterate our Buy Rating but lower our Price Target to $28 from $35 as we push out Margetuximab sales expectations until 2021. A summary of events for 2017 is charted on Page 2 of this report." (3/6/2017)
  • 3. Cowen and Company analysts commented, "MGNX reported 4Q16 results and provided a pipeline update." (3/1/2017)
  • 4. Instinet analysts commented, "We are initiating coverage of MacroGenics with a Buy rating and $41 target price. We recommend accumulating MGNX shares in 2017, as we anticipate several data sets across programs, specifically for the company's B7-H3 franchise. We expect data cross multiple tumor types from ongoing basket trials of both enoblituzumab and bispecific counterpart MGD009 to define initial market opportunities that represent upside to current estimates." (3/1/2017)
  • 5. Stifel Nicolaus analysts commented, "Management's relatively quiet 4Q16 earnings announcement/call was expected following the comprehensive pipeline update provided at the December 2016 R&D Day. The specific timing and magnitude of incremental news flow from both wholly-owned and partnered programs throughout FY17 still remains a bit uncertain ' but we anticipate the finalization of dose and administration schedules for a variety of DART programs to allow for the initiation of dose expansion cohorts in both FY17 and beyond. SOPHIA enrollment appears to remain on track and a newly-implemented trial amendment allowing for Kadcyla-na??ve patients should facilitate the pace of enrollment and eventually expand the addressable market opportunity. We continue to find valuation attractive here. Reduced target price of $42 (previously $51) reflects higher FY17 and forward-year OpEx ' coupled with reduced longer-term collaborative revenue estimates." (3/1/2017)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:

  • Paulo F. Costa, Independent Chairman of the Board
  • Scott Koenig M.D., Ph.D., President, Chief Executive Officer, Director
  • James Karrels MBA, Chief Financial Officer, Vice President, Secretary
  • Ezio Bonvini M.D., Senior Vice President - Research, Chief Scientific Officer
  • Atul Saran, Senior Vice President, General Counsel
  • Eric Risser, Senior Vice President - Business Development and Portfolio Management
  • Kathryn E. Stein Ph.D., Senior Vice President- Product Development & Regulatory Affairs
  • Jon Marc Wigginton, Senior Vice President - Clinical Development and Chief Medical Officer
  • Lynn Cilinski, Vice President, Controller, Treasurer
  • Karen Jean Ferrante M.D., Director

Who owns MacroGenics stock?

MacroGenics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.13%), OppenheimerFunds Inc. (9.50%), BB Biotech AG (6.46%), Blue Ridge Capital L.L.C. (3.88%), Vanguard Group Inc. (3.87%) and Point72 Asset Management L.P. (3.37%). Company insiders that own MacroGenics stock include Ezio Bonvini, Jon Marc Wigginton, Lynn Cilinski and Paulo F Costa. View Institutional Ownership Trends for MacroGenics.

Who sold MacroGenics stock? Who is selling MacroGenics stock?

MacroGenics' stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, FMR LLC, TFS Capital LLC, Morgan Stanley, UBS Asset Management Americas Inc., Point72 Asset Management L.P., Oxford Asset Management and Spark Investment Management LLC. Company insiders that have sold MacroGenics stock in the last year include Jon Marc Wigginton and Lynn Cilinski. View Insider Buying and Selling for MacroGenics.

Who bought MacroGenics stock? Who is buying MacroGenics stock?

MacroGenics' stock was acquired by a variety of institutional investors in the last quarter, including BB Biotech AG, OppenheimerFunds Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Bellevue Group AG, State Street Corp, Renaissance Technologies LLC and Hood River Capital Management LLC. View Insider Buying and Selling for MacroGenics.

How do I buy MacroGenics stock?

Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MacroGenics stock can currently be purchased for approximately $18.25.

MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $33.89 (85.69% upside)

Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Morgan StanleyLower Price TargetEqual Weight$24.00 -> $22.00LowView Rating Details
3/31/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$26.00HighView Rating Details
3/6/2017BTIG ResearchReiterated RatingBuy$35.00 -> $28.00N/AView Rating Details
3/1/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
3/1/2017Stifel NicolausReiterated RatingBuy$51.00 -> $42.00N/AView Rating Details
1/25/2017Citigroup IncLower Price TargetNeutral$32.00 -> $24.00N/AView Rating Details
12/19/2016SunTrust Banks, Inc.Initiated CoverageBuy$30.00N/AView Rating Details
11/3/2016WedbushReiterated RatingOutperform$52.00N/AView Rating Details
6/14/2016Oppenheimer Holdings Inc.Reiterated RatingBuyN/AView Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00N/AView Rating Details
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for MacroGenics (NASDAQ:MGNX)
Earnings by Quarter for MacroGenics (NASDAQ:MGNX)
Earnings History by Quarter for MacroGenics (NASDAQ:MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MacroGenics (NASDAQ:MGNX)
2017 EPS Consensus Estimate: ($4.17)
2018 EPS Consensus Estimate: ($3.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.18)($0.83)($1.03)
Q2 20174($1.17)($0.83)($1.03)
Q3 20174($1.21)($0.85)($1.04)
Q4 20174($1.24)($0.88)($1.07)
Q1 20181($0.96)($0.96)($0.96)
Q2 20181($0.90)($0.90)($0.90)
Q3 20181($0.93)($0.93)($0.93)
Q4 20181($0.96)($0.96)($0.96)
(Data provided by Zacks Investment Research)


Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MacroGenics (NASDAQ:MGNX)
Insider Ownership Percentage: 6.78%
Institutional Ownership Percentage: 81.68%
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)
Insider Trades by Quarter for MacroGenics (NASDAQ:MGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.00View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.00View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.68View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.00View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MacroGenics (NASDAQ:MGNX)
Latest Headlines for MacroGenics (NASDAQ:MGNX)
DateHeadline logoMacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : May 22, 2017 - May 22 at 10:10 AM logoMacroGenics (MGNX) Presents At BofAML 2017 Global Metals, Mining and Steel Conference - May 19 at 11:53 PM logo Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $5.01 Million - May 10 at 11:34 AM logoMacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : May 9, 2017 - May 9 at 11:49 AM logoZacks Investment Research Upgrades MacroGenics Inc (MGNX) to "Hold" - May 9 at 7:16 AM logoMacroGenics Inc (MGNX) Stock Rating Reaffirmed by Morgan Stanley - May 8 at 8:30 PM logoETFs with exposure to MacroGenics, Inc. : May 8, 2017 - May 8 at 6:05 PM logoMacroGenics Inc (MGNX) Receives Average Rating of "Buy" from Analysts - May 8 at 11:10 AM logo-$1.05 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter - May 8 at 10:48 AM logoQ2 2017 EPS Estimates for MacroGenics Inc Increased by Wedbush (MGNX) - May 8 at 8:27 AM logoQ2 2017 Earnings Forecast for MacroGenics Inc (MGNX) Issued By Leerink Swann - May 8 at 8:27 AM logoQ2 2017 EPS Estimates for MacroGenics Inc Lifted by Analyst (MGNX) - May 8 at 8:15 AM logoMacroGenics, Inc. :MGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 - May 5 at 6:49 PM logoBrokers Offer Predictions for MacroGenics Inc's Q1 2018 Earnings (MGNX) - May 5 at 5:32 PM logoMacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results - May 3 at 5:36 PM logoMacroGenics reports 1Q loss - May 3 at 5:36 PM logoInvestor Network: MacroGenics, Inc. to Host Earnings Call - May 3 at 9:22 AM logoMacroGenics (MGNX) Earns News Sentiment Rating of -0.07 - May 2 at 9:34 PM logoMacroGenics (MGNX) Earns Media Impact Score of 0.10 - April 27 at 11:44 PM logoMacroGenics Announces Registered Direct Offering of Common Stock - April 27 at 9:32 AM logoMacroGenics to Present at Two Upcoming Investor Conferences in May - April 26 at 6:47 PM logoMacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call - April 25 at 5:50 PM logoMacroGenics (MGNX) Receiving Very Favorable Media Coverage, Report Finds - April 24 at 2:58 PM logoSomewhat Favorable Media Coverage Somewhat Likely to Affect MacroGenics (MGNX) Share Price - April 22 at 12:38 AM logoMacroGenics Inc (MGNX) SVP Jon Marc Wigginton Sells 15,000 Shares - April 20 at 7:48 PM logoMacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : April 19, 2017 - April 19 at 6:36 PM logoMacroGenics Inc (MGNX) Expected to Announce Quarterly Sales of $5.88 Million - April 19 at 11:56 AM logoMacroGenics (MGNX) Earning Somewhat Negative Media Coverage, Study Shows - April 18 at 2:00 PM logoMacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : April 18, 2017 - April 18 at 10:25 AM logoMacroGenics Inc (MGNX) Expected to Post Earnings of -$0.99 Per Share - April 17 at 9:26 AM logoMacroGenics (MGNX) Given Daily Coverage Optimism Score of -0.15 - April 15 at 12:11 PM logoMacroGenics Inc (MGNX) Given Consensus Rating of "Buy" by Analysts - April 11 at 9:15 AM logoMacroGenics to Present at the Needham Healthcare Conference - GlobeNewswire (press release) - March 31 at 6:37 PM logoMacrogenics (MGNX) Says Eight Posters Based on MacroGenics-developed Molecules Featured at AACR - - March 31 at 6:37 PM logoMacroGenics Inc (MGNX) Now Covered by Analysts at Raymond James Financial, Inc. - March 31 at 12:38 PM logoMacrogenics (MGNX) Says Eight Posters Based on MacroGenics-developed Molecules Featured at AACR - March 31 at 9:39 AM logoEight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017 - March 31 at 9:39 AM logoMacroGenics to Present at the Needham Healthcare Conference - March 29 at 7:09 PM logoMACROGENICS INC Financials - March 7 at 6:17 PM logoCoverage initiated on MacroGenics by Instinet - March 2 at 6:44 PM logoMACROGENICS INC Files SEC form 10-K, Annual Report - March 1 at 10:55 AM logoMACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 1 at 10:55 AM logoEdited Transcript of MGNX earnings conference call or presentation 28-Feb-17 9:30pm GMT - March 1 at 10:55 AM logoMacroGenics Provides Update on Corporate Progress and 2016 Financial Results - February 28 at 6:39 PM logoQ4 2016 MacroGenics Inc Earnings Release - After Market Close - February 28 at 10:08 AM logoMacroGenics to Participate in Two Upcoming Investor Conferences - February 27 at 6:06 PM logoMacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call - February 16 at 6:07 PM logoMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference - GlobeNewswire (press release) - February 10 at 12:40 AM logoMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference - February 9 at 7:32 PM logoMACROGENICS INC Files SEC form 8-K, Financial Statements and Exhibits - January 26 at 9:27 PM



MacroGenics (MGNX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff